Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ardelyx Inc (ARDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,284
  • Shares Outstanding, K 62,130
  • Annual Sales, $ 42,000 K
  • Annual Income, $ -64,340 K
  • 36-Month Beta 1.33
  • Price/Sales 4.50
  • Price/Cash Flow N/A
  • Price/Book 1.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.43
  • Prior Year 0.21
  • Growth Rate Est. (year over year) -290.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.66 +4.89%
on 10/31/18
4.09 -31.78%
on 10/19/18
-0.91 (-24.59%)
since 10/12/18
3-Month
2.66 +4.89%
on 10/31/18
4.60 -39.35%
on 08/29/18
-1.26 (-31.11%)
since 08/13/18
52-Week
2.66 +4.89%
on 10/31/18
8.10 -65.56%
on 01/23/18
-2.86 (-50.62%)
since 11/13/17

Most Recent Stories

More News
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018.

ARDX : 2.79 (-5.42%)
Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ardelyx, Inc. (NASDAQ:ARDX),...

TGTX : 5.28 (-1.49%)
AXTI : 5.45 (-0.91%)
BCRX : 7.14 (-0.14%)
ARDX : 2.79 (-5.42%)
HZO : 23.70 (-1.82%)
OCLR : 7.54 (+1.89%)
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend...

ARDX : 2.79 (-5.42%)
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City. This year's event is the first of...

ARDX : 2.79 (-5.42%)
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting U.S. marketing authorization of tenapanor for the...

ARDX : 2.79 (-5.42%)
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed...

ARDX : 2.79 (-5.42%)
Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDF Solutions, Inc. (NASDAQ:PDFS),...

ALDX : 10.09 (-1.56%)
PDFS : 8.53 (+1.43%)
MYOS : 1.27 (+4.10%)
EVRI : 6.34 (-1.71%)
ARDX : 2.79 (-5.42%)
ENSG : 45.46 (-1.13%)
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second quarter ended June 30, 2018.

ARDX : 2.79 (-5.42%)
Ardelyx, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Ardelyx, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time.

ARDX : 2.79 (-5.42%)
What's in Store for Penumbra (PEN) This Earnings Season?

Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.

EYE : 41.09 (-3.29%)
NTRA : 15.95 (+0.28%)
PEN : 134.17 (-2.53%)
ARDX : 2.79 (-5.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARDX with:

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

2nd Resistance Point 3.24
1st Resistance Point 3.01
Last Price 2.79
1st Support Level 2.66
2nd Support Level 2.54

See More

52-Week High 8.10
Fibonacci 61.8% 6.02
Fibonacci 50% 5.38
Fibonacci 38.2% 4.74
Last Price 2.79
52-Week Low 2.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar